We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




SLAS Hosts First Annual China Conference and Exhibition

By LabMedica International staff writers
Posted on 27 Dec 2010
The newly merged Society for Laboratory Automation and Screening (SLAS; St. More...
Charles, IL, USA) hosted its First Annual China Conference and Exhibition in Shanghai (China), at the Shangri-La Hotel, on December 7-9, 2010. The newly launched event set the framework for future SLAS endeavors in Asia Pacific.

The meeting combined a series of presentations on new technologies and experimental approaches for hit and lead identification with the opportunity for local scientists to network with in an informal and engaging environment.

The conference hosted 25 exclusive scientific lectures presented by eminent scientists. Christopher Lipinski, PhD, from Melior Discovery (Exton, PA, USA) discussed the issue of compound failure in preclinical and clinical development and strategies to reduce this failure rate through improvements to the physiochemical properties of drug candidates.

Wei Zhang PhD, National Institutes of Health Chemical Genomics Center (NIH; Bethesda, MD, USA) presented on the use of cellular phenotypic screens for lead identification to enable the identification of molecules with improved efficacy.

At the exhibition, TTP Labtech (Royston, United Kingdom) launched the Mirrorball, a new laser scanning microplate cytometer designed primarily for the study of antibody/antigen interactions. The new instrument offers increased sensitivity and multiplexing capability compared to existing instruments.

As a complimentary benefit to conference participants, SLAS partnered with the Shanghai Zhangjiang Technology Park (Shanghai, China) for a private pre-event function highlighted by three additional scientific lectures. The primary presentation was given by Xin Xie, PhD, head of assay development, Chinese National Center for Drug Screening (Shanghai, China).

A guided tour of the technology park was given to meeting participants. The park houses 110 research and development institutions and 327 companies including leading pharmaceutical companies.

According to SLAS scientific program committee chair Steven Rees at GlaxoSmithKline (Stevenage, United Kingdom), the conference was "phenomenally successful.” He added, "Bringing SLAS to Shanghai has demonstrated the interest and expertise in drug discovery in China, and the enthusiasm of the local scientists to partner with the SLAS community.”

Related Links:

Society for Laboratory Automation and Screening
GlaxoSmithKline
Melior Discovery
TTP Labtech


New
Gold Member
Hematology Analyzer
Medonic M32B
Portable Electronic Pipette
Mini 96
New
8-Channel Pipette
SAPPHIRE 20–300 µL
New
Gel Cards
DG Gel Cards
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Over 100 new epigenetic biomarkers may help predict cardiovascular disease risk (Photo courtesy of 123RF)

Routine Blood Draws Could Detect Epigenetic Biomarkers for Predicting Cardiovascular Disease Risk

Cardiovascular disease is a leading cause of death worldwide, yet predicting individual risk remains a persistent challenge. Traditional risk factors, while useful, do not fully capture biological changes... Read more

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The VENTANA HER2 (4B5) test is now CE-IVDR approved (Photo courtesy of Roche)

Companion Diagnostic Test Identifies HER2-Ultralow Breast Cancer and Biliary Tract Cancer Patients

Breast cancer is the most common cancer in Europe, with more than 564,000 new cases and 145,000 deaths annually. Metastatic breast cancer is rising in younger populations and remains the leading cause... Read more

Pathology

view channel
Image: An adult fibrosarcoma case report has shown the importance of early diagnosis and targeted therapy (Photo courtesy of Sultana and Sailaja/Oncoscience)

Accurate Pathological Analysis Improves Treatment Outcomes for Adult Fibrosarcoma

Adult fibrosarcoma is a rare and highly aggressive malignancy that develops in connective tissue and often affects the limbs, trunk, or head and neck region. Diagnosis is complex because tumors can mimic... Read more

Technology

view channel
Image: Conceptual design of the CORAL capsule for microbial sampling in the small intestine (H. Mohammed et al., Device (2025). DOI: 10.1016/j.device.2025.100904)

Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine

The gut microbiome has been linked to conditions ranging from immune disorders to mental health, yet conventional stool tests often fail to capture bacterial populations in the small intestine.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.